StocksMedium•16 November 2026•
1 min read
FDA Approves Roche's Gazyva for Rare Kidney Disease Treatment
Key Facts
1The U.S. FDA has approved Roche's Gazyva (obinutuzumab) for the treatment of adults with primary membranous nephropathy.
The U.S. FDA has approved Roche's Gazyva (obinutuzumab) for the treatment of adults with primary membranous nephropathy. Benzinga reported that the approval expands the clinical indications for the drug, providing a new treatment option for patients with this rare kidney disease.
The regulatory milestone follows recent positive feedback for Gazyva in the European Union regarding a different kidney condition. RHHBY closed at $60.3 on November 13, 2026, having reached a day high of $60.49 and a low of $60.05 during that session.